Overview

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Status:
Completed

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

This study is to characterize the effect of cobicistat-based regimens on parameters of renal function in participants with HIV infection and who have mild to moderate renal impairment, and to assess the safety and tolerability of the regimens in order to generate appropriate dosing recommendations.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Cobicistat
Darunavir
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Tenofovir